Non-clinical safety assessment of drinabant, a cannabinoid receptor (CB-1) antagonist, for acute cannabinoid overdose (ACO). POP: 09/25/2020 to 03/24/2021.
Ended Awarded Last action
- Contract number
- 75N95020F00003
- Awardee
-
IIT Research Institute UEI DGBUFQYMKWB5 Part of Illinois Institute Of Technology
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $751,371
Award facts
- Opportunity
-
- CRO Support for NCATS In Vitro and In Vivo Toxicology Studies Pre-Solicitation · N01TR17200215 · Posted Apr 7, 2020
- Contract value 100% obligated
- $751,370.91 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 4 offers Multiple Award, Fair Opportunity
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Chicago, IL 60616, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$1,008,219 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $1,425,732 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $10,092 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $323,766 |
About this award
The National Institute on Drug Abuse issued a delivery order to IIT Research Institute on September 25, 2020, with a ceiling value of $751,370.91, under the parent IDIQ "CRO Support for NCATS In Vitro and In Vivo Toxicology Studies" for non-clinical safety assessment of drinabant, a cannabinoid receptor antagonist, and related contract research organization support for in vitro and in vivo toxicology studies.
Place of performance is Chicago, IL. The original period of performance ran from September 25, 2020, to March 24, 2021, though the order's ultimate completion date is December 31, 2024. Pricing is cost-plus-fixed-fee.
IIT Research Institute is a non-profit contract research organization and subsidiary of Illinois Institute of Technology, specializing in preclinical drug development and toxicology services for federal agencies including NIH institutes and NCATS.
Service Contract Inventory reporting shows actual government-invoiced labor ranging from $754 in FY2020 to a peak of $288,000 in FY2023, with 2.6 FTEs and 2,611 contractor hours across the reported period. FY2024 invoicing was $212,000 across 86 hours at $2,456.96 per hour. The derived hourly rate has risen across years, with no subcontractors reported; IIT self-performed all invoiced hours.
Quick answers
Who was awarded contract 75N95020F00003?
75N95020F00003 was awarded to IIT Research Institute by National Institute on Drug Abuse (National Institutes of Health) on September 25, 2020.
How much is contract 75N95020F00003 worth?
The government has obligated $751,371 on 75N95020F00003.
Is contract 75N95020F00003 an order under another contract?
Yes. 75N95020F00003 is a delivery order under HHSN271201700016I, an indefinite delivery contract, on CRO Support for NCATS In Vitro and In Vivo Toxicology Studies.
Was contract 75N95020F00003 competed?
The extent of competition for 75N95020F00003 was full and open competition. The government received 4 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award